For research use only. Not for therapeutic Use.
Motolimod (Cat No.:I005515), referred to as VTX 2337, VTX 2337 is a selective and potent Toll-like receptor 8 (TLR8) agonist and also stimulates IFNγ production by NK cells, enhances cytolytic function of NK cells, and enhances ADCC.
| Catalog Number | I005515 |
| CAS Number | 926927-61-9 |
| Synonyms | 2-amino-N,N-dipropyl-8-[4-(1-pyrrolidinylcarbonyl)phenyl]-3H-1-benzazepine-4-carboxamide |
| Molecular Formula | C28H34N4O2 |
| Purity | ≥95% |
| Target | Toll-like Receptor (TLR) |
| Solubility | 10 mM in DMSO |
| Storage | -20°C |
| IC50 | 100 nM(EC50) |
| InChI | InChI=1S/C28H34N4O2/c1-3-13-31(14-4-2)28(34)24-17-23-12-11-22(18-25(23)30-26(29)19-24)20-7-9-21(10-8-20)27(33)32-15-5-6-16-32/h7-12,17-18H,3-6,13-16,19H2,1-2H3,(H2,29,30) |
| InChIKey | QSPOQCXMGPDIHI-UHFFFAOYSA-N |
| SMILES | O=C(N1CCCC1)C(C=C2)=CC=C2C3=CC(N=C(N)CC(C(N(CCC)CCC)=O)=C4)=C4C=C3 |
| Reference | </br>1:A phase 2, randomized, double-blind, placebo- controlled study of chemo-immunotherapy combination using motolimod with pegylated liposomal doxorubicin in recurrent or persistent ovarian cancer: a Gynecologic Oncology Group partners study. Monk BJ, Brady MF, Aghajanian C, Lankes HA, Rizack T, Leach J, Fowler JM, Higgins R, Hanjani P, Morgan M, Edwards R, Bradley W, Kolevska T, Foukas P, Swisher EM, Anderson KS, Gottardo R, Bryan JK, Newkirk M, Manjarrez KL, Mannel RS, Hershberg RM, Coukos G.Ann Oncol. 2017 May 1;28(5):996-1004. doi: 10.1093/annonc/mdx049. PMID: 28453702 Free PMC Article</br>2:Phase Ib Trial of the Toll-like Receptor 8 Agonist, Motolimod (VTX-2337), Combined with Cetuximab in Patients with Recurrent or Metastatic SCCHN. Chow LQM, Morishima C, Eaton KD, Baik CS, Goulart BH, Anderson LN, Manjarrez KL, Dietsch GN, Bryan JK, Hershberg RM, Disis ML, Martins RG.Clin Cancer Res. 2017 May 15;23(10):2442-2450. doi: 10.1158/1078-0432.CCR-16-1934. Epub 2016 Nov 3. PMID: 27810904 </br>3:Motolimod effectively drives immune activation in advanced cancer patients. Dietsch GN.Oncoimmunology. 2016 Feb 9;5(5):e1126037. doi: 10.1080/2162402X.2015.1126037. eCollection 2016 May. PMID: 27467937 Free PMC Article</br>4:Late-Stage Cancer Patients Remain Highly Responsive to Immune Activation by the Selective TLR8 Agonist Motolimod (VTX-2337). Dietsch GN, Randall TD, Gottardo R, Northfelt DW, Ramanathan RK, Cohen PA, Manjarrez KL, Newkirk M, Bryan JK, Hershberg RM.Clin Cancer Res. 2015 Dec 15;21(24):5445-52. doi: 10.1158/1078-0432.CCR-15-0578. Epub 2015 Jul 7. PMID: 26152744 Free Article |
